因结直肠癌症状就诊于英国初级保健机构的成人粪便免疫化学检测:一项对14 487例连续检测申请的回顾性队列研究
该回顾性队列研究分析了2017年3月至2020年3月英国牛津郡初级保健 routine 实践中14 487例连续FIT检测申请,其中9 896例成人随访至少6个月。FIT阈值≥10 µg Hb/g粪便对结直肠癌的敏感性为90.5%,特异性为91.3%,阳性预测值为10.1%,阴性预测值为99.9%。作者结论认为≥10 µg Hb/g粪便的FIT阈值适合用于对出现严重结直肠疾病症状的初级保健成人患者进行分诊。
要点
- FIT阈值≥10 µg Hb/g粪便对结直肠癌敏感性90.5%、特异性91.3%、阳性预测值10.1%、阴性预测值99.9%。
- 使用≥10 µg Hb/g粪便阈值,10%成人需接受检查以检出91%的癌症,需检查10例发现1例癌症。
- FIT可用于重新划分因COVID-19大流行导致检查延迟的结直肠癌症状转诊患者的优先级。
核心结论
- FIT阈值≥10 µg Hb/g粪便适合用于对出现严重结直肠疾病症状的初级保健成人患者进行分诊。
- FIT可用于重新划分因COVID-19大流行导致检查延迟的结直肠癌症状转诊患者的优先级。
研究设计与样本
- 回顾性队列研究,分析2017年3月至2020年3月英国牛津郡初级保健 routine 实践中14 487例连续FIT检测申请。
- 粪便样本采用HM-JACKarc FIT方法分析,记录临床细节,通过链接医院记录随访最多36个月以寻找良性和严重结直肠疾病证据。
- 共9 896例成人患者至少有6个月随访数据纳入诊断准确性分析,按性别、年龄组和FIT阈值报告诊断准确性。
主要发现
- 在9 896例至少随访6个月的成人患者中,FIT结果≥10 µg Hb/g粪便对结直肠癌的敏感性为90.5%(95% CI 84.9%-96.1%),特异性为91.3%(95% CI 90.8%-91.9%),阳性预测值为10.1%(95% CI 8.15%-12.0%),阴性预测值为99.9%(95% CI 99.8%-100.0%)。
- 对严重结直肠疾病的阳性预测值和特异性高于单独结直肠癌,而敏感性和阴性预测值低于单独结直肠癌。
- 所有成人的曲线下面积未因性别或提高检测最低年龄而发生实质性变化。
- 使用≥10 µg Hb/g粪便阈值时,10%的成人需接受检查以检出91%的癌症,需检查10例发现1例癌症;使用≥7、≥50和≥150 µg Hb/g粪便阈值时,分别有11%、4%和3%的成人需接受检查,分别检出91%、74%和54%的癌症。
关键数值与推荐
- FIT阈值≥10 µg Hb/g粪便对结直肠癌的敏感性为90.5%(95% CI 84.9%-96.1%),特异性为91.3%(95% CI 90.8%-91.9%),阳性预测值为10.1%(95% CI 8.15%-12.0%),阴性预测值为99.9%(95% CI 99.8%-100.0%)。
- 使用≥10 µg Hb/g粪便阈值时,10%的成人需接受检查以检出91%的癌症,需检查10例发现1例癌症。
- 使用≥7、≥50和≥150 µg Hb/g粪便阈值时,分别有11%、4%和3%的成人需接受检查,分别检出91%、74%和54%的癌症。
临床怎么用
- 英国国家卫生与临床优化研究所(NICE)推荐使用FIT对出现症状的初级保健患者进行分诊以进一步检查结直肠癌。
- 作者结论认为FIT阈值≥10 µg Hb/g粪便适合用于对出现严重结直肠疾病症状的初级保健成人患者进行分诊。
- 作者结论认为FIT可用于重新划分因COVID-19大流行导致检查延迟的结直肠癌症状转诊患者的优先级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Faecal immunochemical testing (FIT) is recommended by the National Institute for Health and Care Excellence (NICE) to triage symptomatic primary care patients for further investigation of colorectal cancer. AIM: To ascertain the diagnostic performance of FIT in symptomatic adult primary care patients. METHODS: Faecal samples from routine primary care practice in Oxfordshire, UK were analysed using the HM-JACKarc FIT method between March 2017 and March 2020. Clinical details were recorded. Patients were followed for up to 36 months in linked hospital records for evidence of benign and serious (colorectal cancer, high-risk adenomas and bowel inflammation) colorectal disease. The diagnostic accuracy of FIT is reported by gender, age group and FIT threshold. RESULTS: In 9896 adult patients with at least 6-month follow-up, a FIT result ≥10 µg Hb/g faeces had a sensitivity for colorectal cancer of 90.5% (95% CI 84.9%-96.1%), specificity 91.3% (90.8%-91.9%), positive predictive value (PPV) 10.1% (8.15%-12.0%) and negative predictive value (NPV) 99.9% (99.8%-100.0%). The PPV and specificity for serious colorectal disease were higher and the sensitivity and NPV lower than for colorectal cancer alone. The area under the curve for all adults did not change substantially by gender or by increasing the minimum age of testing. Using ≥10 µg Hb/g faeces, 10% of adults would be investigated to detect 91% of cancers, a number needed to scope of ten to detect one cancer. Using ≥7, ≥50 and ≥150 µg Hb/g faeces, 11%, 4% and 3% of adults would be investigated, and 91%, 74% and 54% cancers detected, respectively. CONCLUSION: A FIT threshold of ≥10 µg Hb/g faeces would be appropriate to triage adult patients presenting to primary care with symptoms of serious colorectal disease. FIT may be used to reprioritise patients referred with colorectal cancer symptoms whose investigations have been delayed by the COVID-19 pandemic.
引用
- Nicholson BD, James T, Paddon M, et al. Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests. Aliment Pharmacol Ther. 2020. PMID: 32677733. doi:10.1111/apt.15969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。